Phenotypeca provides novel biologics production strains of the regulatory friendly baker's yeast, Saccharomyces cerevisiae for the production of biologics.
We offer world leading yeast technology to rapidly provide cost-effective production strains optimised for specific biotechnology processes. This is achieved by harnessing the natural diversity in libraries containing up to a billion genetically distinct yeast cells, to identify those with the ideal phenotypes and performance characteristics for industrial process conditions.
Working with our customers we aim to improve access to life-saving medicines and promote sustainable manufacturing. With baker's yeast now fully established for the safe and economic production of FDA approved biologics, such as insulins and vaccines, our technology is ideal for taking bioprocesses to the next level.